MedTrace Logo

Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients

NCT01934452 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77

Last updated 2023-11-13

Study results available
· View outcomes & findings →

Summary

This prospective study will investigate the characteristics of mRCC patients at time of CR in comparison with mRCC patients non on CR treated with Sunitinib, in order to provide some answers/ refection leads to the following questions :

Can we identify blood specificity at time of CR vs non on CR? Shall we distinguish CR with sunitinib alone from combined CR (sunitinib with local treatment), while in clinical report these 2 cohorts present similar time to recurrence (ALBIGES, ASCO 2010)? Can we identify potential predictive serum biomarkers of recurrence? (With the aim of isolating blood biomarker that can help on treatment discontinuation decision?)

Conditions

  • Complete Remission in Renal Cell Carcinoma

Interventions

DRUG

sunitinib

50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months

DRUG

sunitinib

50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-21
Primary Completion
2022-01-19
Completion
2022-01-19

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01934452 on ClinicalTrials.gov